Ultragenyx Pharmaceutical Inc [RARE] stock prices are down -0.97% to $31.51 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RARE shares have gain 5.17% over the last week, with a monthly amount glided 13.22%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On June 06, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $67 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $77 on April 22, 2024. Wells Fargo initiated its recommendation with a Overweight and recommended $72 as its price target on December 08, 2023. In a note dated June 06, 2023, Evercore ISI upgraded an Outperform rating on this stock and boosted its target price from $60 to $80.
The stock price of Ultragenyx Pharmaceutical Inc [RARE] has been fluctuating between $25.81 and $60.37 over the past year. Currently, Wall Street analysts expect the stock to reach $115 within the next 12 months. Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] shares were valued at $31.51 at the most recent close of the market. An investor can expect a potential return of 264.96% based on the average RARE price forecast.
Analyzing the RARE fundamentals
The Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] reported sales of 610.16M for trailing twelve months, representing a surge of 13.24%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.83%, Pretax Profit Margin comes in at -0.87%, and Net Profit Margin reading is -0.87%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -2.37 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of5.84.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.20 points at the first support level, and at 30.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.85, and for the 2nd resistance point, it is at 32.18.
Ratios To Look Out For
It’s worth pointing out that Ultragenyx Pharmaceutical Inc [NASDAQ:RARE]’s Current Ratio is 2.45. As well, the Quick Ratio is 2.30, while the Cash Ratio is 0.63. Considering the valuation of this stock, the price to sales ratio is 4.98, the price to book ratio is 20.03.
Transactions by insiders
Recent insider trading involved Huizenga Theodore Alan, SVP, Chief Accounting Officer, that happened on Sep 05 ’25 when 84.0 shares were sold. Director, Sanders Corazon (Corsee) D. completed a deal on Jun 20 ’25 to sell 2405.0 shares. Meanwhile, Director CORAZON D. SANDERS bought 2405.0 shares on Jun 20 ’25.
